FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns pharmaceutics, more specifically a prolonged-release composition of tedisamil or its pharmaceutically acceptable salt to be used in prevention and treatment of atrial fibrillation, atrial flutter and myocardial ischemia, containing 5 to 40 wt % of tedisamil or its pharmaceutically acceptable salt, 30 to 85 wt % of a water-swellable polymeric matrix containing hydroxypropylmethylcellulose (HPMC) of high or medium viscosity and hydrohyethyltcellulose (HEC) of high or medium viscosity in the ratio HPMC/HEC=1/0.85-1/1.2, 2.5 to 5 wt % of a salt capable to recover carbon-dioxide gas in the gastric medium, and 0.5 to 10 wt % of alginic acid.
EFFECT: invention allows providing tedisamil composition expressing improved bioavailability and causing less by-effects of gastrointestinal tract.
5 cl, 6 ex, 4 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION DISTINGUISHED BY PROLONGED RELEASE INDEPENDENT OF IONIC FORCE | 2001 |
|
RU2285519C2 |
| PHARMACEUTICAL COMPOSITION OF SLOW RELEASE, CONTAINING APLINDOR AND ITS DERIVATIVES | 2004 |
|
RU2376988C2 |
| DRUG COMPOSITIONS CONTAINING CONTROLLED RELEASE HYPROMELLOSE MATRIXES | 2006 |
|
RU2414241C2 |
| SOLID DOSAGE FORMS OF ONDANSETRON WITH PROLONGED RELEASE FOR TREATING SYMPTOMS OF NAUSEA, VOMITING AND DIARRHEA | 2015 |
|
RU2706708C2 |
| SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION AND METHOD FOR ITS PREPARING | 2002 |
|
RU2234915C2 |
| SOLID MOLECULAR DISPERSION | 2012 |
|
RU2600816C2 |
| ANTIEMETIC EXTENDED RELEASE SOLID DOSAGE FORMS | 2014 |
|
RU2679448C2 |
| MEDICINE DELIVERY REGULATED SYSTEM CONTAINED IN STOMACH | 2002 |
|
RU2325152C2 |
| TABLETS OF TAMSULOSIN WITH MODIFIED RELEASE | 2002 |
|
RU2335280C2 |
| PHARMACEUTICAL COMPOSITIONS FOR PROLONGED RELEASE PHENYLEPHRINE | 2007 |
|
RU2450803C2 |
